Shopping Cart 0
Cart Subtotal
USD 0

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Pipeline Review, H2 2017'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Pipeline Review, H2 2017' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Psychiatric Disorders, Smoking Addiction, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Major Depressive Disorder, Neurology, Nicotine Addiction and Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Overview

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Companies Involved in Therapeutics Development

H. Lundbeck AS

NeuroDerm Ltd

Saniona AB

Sopharma AD

Suven Life Sciences Ltd

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Drug Profiles

(nicotine + opipramol hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytisine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-9283-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Neurological and Psychiatric disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-911-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)-Product Development Milestones

Featured News & Press Releases

Nov 14, 2017: Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects

Oct 26, 2017: Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine

Oct 04, 2017: Achieve Announces Advancement of Cytisine Clinical Development Program

Aug 16, 2017: Achieve Announces Initiation of Cytisine Clinical Development Program

Aug 10, 2017: Achieve Announces FDA Acceptance of the Investigational New Drug Application for Cytisine as a Smoking Cessation Treatment

May 25, 2017: Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor antagonist for Major Depressive Disorder

Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")

Dec 16, 2016: FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX (varenicline) Labeling

Sep 14, 2016: FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer'sSmoking Cessation Therapy, CHANTIX (varenicline)

May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP

Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet

Sep 04, 2015: Quit-smoking drug safer than thought

Mar 09, 2015: FDA updates label for stop smoking drug Chantix

Mar 09, 2015: Suven Life secures One (1) Product Patent each in Eurasia and Israel

Oct 16, 2014: Statement Regarding FDA Advisory Committees' Vote on CHANTIX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by H. Lundbeck AS, H2 2017

Pipeline by NeuroDerm Ltd, H2 2017

Pipeline by Saniona AB, H2 2017

Pipeline by Sopharma AD, H2 2017

Pipeline by Suven Life Sciences Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

H. Lundbeck AS

NeuroDerm Ltd

Saniona AB

Sopharma AD

Suven Life Sciences Ltd